Karo Pharma AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
47,029.00
30,060.00
69,095.00
347,261.00
657,606.00
1,615
Cost of Goods Sold (COGS) incl. D&A
-
-
43,647.00
218,280.00
377,446.00
894
Gross Income
-
-
25,448.00
128,981.00
280,160.00
721
SG&A Expense
71,529.00
87,740.00
61,372.00
126,991.00
170,352.00
304
EBIT
25,934.00
59,547.00
35,924.00
1,990.00
109,808.00
418
Unusual Expense
3,424.00
-
38,426.00
2,193.00
27,615.00
1
Non Operating Income/Expense
117.00
278.00
438.00
29,851.00
12,097.00
3
Interest Expense
18.00
13.00
509.00
9,810.00
50,404.00
142
Pretax Income
22,078.00
59,282.00
75,297.00
19,838.00
19,692.00
290
Income Tax
-
-
2,894.00
75,718.00
6,346.00
367
Equity in Affiliates
-
-
-
-
1,159.00
-
Consolidated Net Income
22,078.00
59,282.00
78,191.00
95,556.00
14,505.00
657
Net Income
22,078.00
59,282.00
77,632.00
95,556.00
14,516.00
657
Net Income After Extraordinaries
22,078.00
59,282.00
77,632.00
95,556.00
14,516.00
657
Net Income Available to Common
22,078.00
59,282.00
77,632.00
95,556.00
14,516.00
657
EPS (Basic)
0.49
1.29
1.45
1.33
0.16
4.63
Basic Shares Outstanding
40,668.90
45,406.60
53,622.70
71,624.60
89,442.60
142
EPS (Diluted)
0.54
1.31
1.45
1.33
0.16
4.63
Diluted Shares Outstanding
40,668.90
45,406.60
53,622.70
71,624.60
89,442.60
142
EBITDA
24,500.00
57,680.00
32,771.00
21,734.00
171,551.00
636
Non-Operating Interest Income
333.00
-
-
-
-
18
Minority Interest Expense
-
-
559.00
-
11.00
-

About Karo Pharma AB

View Profile
Address
Nybrokajen 7
Stockholm AB 111 48
Sweden
Employees -
Website http://www.karopharma.se
Updated 07/08/2019
Karo Pharma AB is a healthcare company, which engages in the research, development, and distribution of innovative drugs for key medical needs. It focuses on the project portfolio consists of RORgamma, Multiple Sclerosis and Cancer, and T268A Common Cold Spray. The company was founded in 1987 and is headquartered in Stockholm, Sweden.